DK97890A - Fremgangsmaade til fremstilling af mevalolactonanaloge - Google Patents

Fremgangsmaade til fremstilling af mevalolactonanaloge Download PDF

Info

Publication number: DK97890A
Authority: DK; Denmark
Prior art keywords: hydrogen; alkyl; image; general formula; compound
Prior art date: 1982-11-22

Application number

DK097890A

Other languages

English (en)

Other versions

DK165244C (da

DK97890D0 (da

DK165244B (da

Inventor

Faizulla Gulamhusein Kathawala

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-11-22

Filing date

1990-04-19

Publication date

1990-04-19

1990-04-19 Application filed by Sandoz Ag filed Critical Sandoz Ag

1990-04-19 Publication of DK97890D0 publication Critical patent/DK97890D0/da

1990-04-19 Publication of DK97890A publication Critical patent/DK97890A/da

1992-10-26 Publication of DK165244B publication Critical patent/DK165244B/da

1993-03-22 Application granted granted Critical

1993-03-22 Publication of DK165244C publication Critical patent/DK165244C/da

Links

239000001257 hydrogen Substances 0.000 abstract 13
229910052739 hydrogen Inorganic materials 0.000 abstract 13
150000002431 hydrogen Chemical group 0.000 abstract 8
150000001875 compounds Chemical class 0.000 abstract 7
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 4
229910052801 chlorine Chemical group 0.000 abstract 4
239000000460 chlorine Chemical group 0.000 abstract 4
229910052731 fluorine Inorganic materials 0.000 abstract 4
239000011737 fluorine Chemical group 0.000 abstract 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
-1 C1-2-alkyl Substances 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 2
150000002148 esters Chemical class 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
230000003301 hydrolyzing effect Effects 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
125000000422 delta-lactone group Chemical group 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
150000002596 lactones Chemical class 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Indole Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrane Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK097890A 1982-11-22 1990-04-19 Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler DK165244C (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US44366882A	1982-11-22	1982-11-22
US44366882		1982-11-22
US54885083A	1983-11-04	1983-11-04
US54885083		1983-11-04
EP8300308		1983-11-18
PCT/EP1983/000308 WO1984002131A1 (fr)	1982-11-22	1983-11-18	Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques

Publications (4)

Publication Number	Publication Date
DK97890D0 DK97890D0 (da)	1990-04-19
DK97890A true DK97890A (da)	1990-04-19
DK165244B DK165244B (da)	1992-10-26
DK165244C DK165244C (da)	1993-03-22

Family

ID=27033614

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK359284A DK359284D0 (da)	1982-11-22	1984-07-20	Mevalolactonanaloge
DK097890A DK165244C (da)	1982-11-22	1990-04-19	Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK359284A DK359284D0 (da)	1982-11-22	1984-07-20	Mevalolactonanaloge

Country Status (18)

Country	Link
EP (1)	EP0114027B1 (da)
JP (1)	JPH0347167A (da)
AT (1)	ATE31718T1 (da)
AU (1)	AU570021B2 (da)
CA (1)	CA1210405A (da)
CY (1)	CY1579A (da)
DE (2)	DE3375137D1 (da)
DK (2)	DK359284D0 (da)
FI (1)	FI77228C (da)
GR (1)	GR79042B (da)
HK (1)	HK11191A (da)
HU (1)	HU204253B (da)
IE (1)	IE56262B1 (da)
IL (1)	IL70286A (da)
LU (1)	LU88670I2 (da)
NL (1)	NL950022I2 (da)
NZ (1)	NZ206338A (da)
WO (1)	WO1984002131A1 (da)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5354772A (en) *	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) *	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5001255A (en) *	1984-12-04	1991-03-19	Sandoz Pharm. Corp.	Idene analogs of mevalonolactone and derivatives thereof
ATE60571T1 (de) *	1984-12-04	1991-02-15	Sandoz Ag	Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) *	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
US4851427A (en) *	1985-10-25	1989-07-25	Sandoz Pharm. Corp.	Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
AU598775B2 (en) *	1985-10-25	1990-07-05	Sandoz Ag	Heterocyclic analogs of mevalonolactone
IL83821A0 (en) *	1986-09-10	1988-02-29	Sandoz Ag	Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
US4751235A (en) *	1986-12-23	1988-06-14	Sandoz Pharm. Corp.	Anti-atherosclerotic indolizine derivatives
US4735958A (en) *	1986-12-22	1988-04-05	Warner-Lambert Company	Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4898949A (en) *	1987-02-25	1990-02-06	Bristol-Myers Company	Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) *	1987-02-25	1990-01-30	Bristol-Meyers Company	Antihypercholesterolemic tetrazole compounds
US4894386A (en) *	1987-04-15	1990-01-16	Ici Americas Inc.	Aliphatic carboxamides
US4904646A (en) *	1987-05-22	1990-02-27	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) *	1987-05-22	1992-02-25	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US5185328A (en) *	1987-08-20	1993-02-09	Nissan Chemical Industries Ltd.	Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
CA1336714C (en) *	1987-08-20	1995-08-15	Yoshihiro Fujikawa	Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) *	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
DE3739882A1 (de) *	1987-11-25	1989-06-08	Bayer Ag	Substituierte hydroxylamine
US4868185A (en) *	1987-12-10	1989-09-19	Warner-Lambert Company	6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) *	1988-01-27	1989-04-18	Sandoz Pharm. Corp.	Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
AU2888289A (en) *	1988-01-27	1989-07-27	May & Baker Limited	Isoquinolinones
NO890522L (no) *	1988-02-25	1989-08-28	Bayer Ag	Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) *	1988-04-26	1991-06-18	Nissan Chemical Industries Ltd.	Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) *	1988-04-26	1999-05-17	日産化学工業株式会社	ピラゾロピリジン系メバロノラクトン類
US5010205A (en) *	1988-08-23	1991-04-23	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl intermediates
US4870187A (en) *	1988-08-23	1989-09-26	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl compounds
US5506219A (en) *	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors
NZ230121A (en) *	1988-08-29	1993-08-26	Squibb & Sons Inc	Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
MY105067A (en) *	1988-10-13	1994-07-30	Novartis Ag	Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof.
JPH04270285A (ja) *	1988-11-14	1992-09-25	Nissan Chem Ind Ltd	ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) *	1989-04-06	1990-10-11	Bayer Ag	Substituierte 1,8-naphthyridine
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) *	1989-08-22	1989-10-04	Fujisawa Pharmaceutical Co	Pyrroloquinoline compounds
IT1237792B (it) *	1989-12-21	1993-06-17	Zambon Spa	Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU217629B (hu) *	1991-12-12	2000-03-28	Novartis Ag.	Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
DE4243279A1 (de) *	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
JP2736599B2 (ja) *	1993-07-23	1998-04-02	株式会社キッツ	ボールバルブのシート構造
DE19513716A1 (de) *	1995-02-01	1996-08-08	Bayer Ag	Substituierte 2-Phenylindol-Derivate
US6425881B1 (en)	1994-10-05	2002-07-30	Nitrosystems, Inc.	Therapeutic mixture useful in inhibiting lesion formation after vascular injury
WO1997049681A1 (en) *	1996-06-24	1997-12-31	Astra Aktiebolag (Publ)	Polymorphic compounds
EP0988289A2 (en)	1997-06-05	2000-03-29	Takeda Pharmaceutical Company Limited	Heterocyclic compounds, their production and use
US7939105B2 (en)	1998-11-20	2011-05-10	Jagotec Ag	Process for preparing a rapidly dispersing solid drug dosage form
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
WO2001092223A1 (en)	2000-05-26	2001-12-06	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of indole derivatives and intermediates of the process
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
CN1509180A (zh)	2001-04-18	2004-06-30	ԭ��ø�	用脂肪族聚胺治疗综合症x的方法
DE60226044T2 (de) *	2001-08-03	2009-05-14	Ciba Holding Inc.	Kristalline formen von fluvastatin-natrium
US6696473B2 (en)	2001-12-21	2004-02-24	X-Ceptor Therapeutics, Inc.	Heterocyclic modulators of nuclear receptors
AU2003230835A1 (en)	2002-04-12	2003-10-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
JP4553899B2 (ja)	2003-08-21	2010-09-29	メルクフロストカナダリミテツド	カテプシンシステインプロテアーゼ阻害剤
EP1510208A1 (en)	2003-08-22	2005-03-02	Fournier Laboratories Ireland Limited	Pharmaceutical composition comprising a combination of metformin and statin
CN100404479C (zh) *	2003-08-27	2008-07-23	住友化学株式会社	芳族不饱和化合物的制备方法
US8227434B1 (en)	2003-11-04	2012-07-24	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Materials and methods for treating oncological disorders
KR20070085874A (ko) *	2004-12-09	2007-08-27	머크 앤드 캄파니 인코포레이티드	에스트로겐 수용체 조절제
US7709508B2 (en)	2004-12-09	2010-05-04	Merck Sharp & Dohme	Estrogen receptor modulators
US8722734B2 (en)	2005-03-02	2014-05-13	Merck Sharp & Dohme Corp.	Composition for inhibition of cathepsin K
WO2007002563A1 (en)	2005-06-27	2007-01-04	Exelixis, Inc.	Imidazole based lxr modulators
EP1912953B1 (en) *	2005-07-28	2016-08-17	LEK Pharmaceuticals d.d.	Process for the synthesis of rosuvastatin calcium
TW200804345A (en)	2005-08-30	2008-01-16	Novartis Ag	Substituted benzimidazoles and methods of preparation
WO2007059372A2 (en)	2005-11-09	2007-05-24	St. Jude Children's Research Hospital	Use of chloroquine to treat metabolic syndrome
DK2010528T3 (da)	2006-04-19	2018-01-15	Novartis Ag	6-O-Substituerede benzoxazol og benzothiazolforbindelser og fremgangsmåder til en inhibering af CSF-1R-signalering
ATE431818T1 (de)	2006-04-20	2009-06-15	Italiana Sint Spa	Verfahren zur herstellung von fluvastatin-natrium
ES2378281T3 (es)	2006-07-05	2012-04-10	Nycomed Gmbh	Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
ES2431163T3 (es)	2007-03-01	2013-11-25	Novartis Ag	Inhibidores de PIM quinasa y métodos para su uso
BRPI0812159A2 (pt)	2007-05-21	2017-05-02	Novartis Ag	inibidores de csf-1r, composições e métodos de uso
ES2330184B1 (es)	2008-06-03	2010-07-05	Neuron Biopharma, S.A.	Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
EP2327682A1 (en)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl)	2008-12-19	2013-12-31	Krka, D.D., Novo Mesto	Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
HRP20170194T1 (hr)	2009-05-28	2017-05-19	Exelixis Patent Company Llc	Lxr modulatori
EP2440058A4 (en)	2009-06-12	2012-11-21	Dana Farber Cancer Inst Inc	MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
BR112012023021A2 (pt)	2010-03-16	2016-05-31	Dana Farber Cancer Inst Inc	compostos de indazol e seus usos
US8372877B2 (en)	2010-04-16	2013-02-12	Cumberland Pharmaceuticals	Stabilized statin formulations
JPWO2012046772A1 (ja)	2010-10-06	2014-02-24	国立大学法人東京大学	リンパ浮腫予防治療剤
WO2012112363A1 (en)	2011-02-14	2012-08-23	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
AR088728A1 (es)	2011-03-25	2014-07-02	Bristol Myers Squibb Co	Moduladores de lxr como prodroga de imidazol
WO2013074986A1 (en)	2011-11-17	2013-05-23	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
EP2797641B1 (en)	2011-12-29	2019-07-10	Trustees Of Tufts College	Functionalization of biomaterials to control regeneration and inflammation responses
US10112927B2 (en)	2012-10-18	2018-10-30	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9758522B2 (en)	2012-10-19	2017-09-12	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
EP2968275B1 (en)	2013-03-15	2017-11-29	Bristol-Myers Squibb Company	Lxr modulators
EP2810644A1 (en)	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Oral formulation for the treatment of cardiovascular diseases
CA2923272A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
WO2015051479A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058140A1 (en)	2013-10-18	2015-04-23	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015120580A1 (en)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
WO2015164604A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
EP3307728A4 (en)	2015-06-12	2019-07-17	Dana Farber Cancer Institute, Inc.	COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
JP7028766B2 (ja)	2015-09-09	2022-03-02	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼの阻害剤
JP7590185B2 (ja)	2018-06-25	2024-11-26	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
WO2020140098A1 (en)	2018-12-28	2020-07-02	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof

1983
- 1983-11-18 WO PCT/EP1983/000308 patent/WO1984002131A1/de not_active Ceased
- 1983-11-18 AU AU22612/83A patent/AU570021B2/en not_active Expired
- 1983-11-18 HU HU84284A patent/HU204253B/hu unknown
- 1983-11-21 GR GR73028A patent/GR79042B/el unknown
- 1983-11-21 IL IL70286A patent/IL70286A/xx not_active IP Right Cessation
- 1983-11-21 NZ NZ206338A patent/NZ206338A/en unknown
- 1983-11-21 IE IE2713/83A patent/IE56262B1/en not_active IP Right Cessation
- 1983-11-22 EP EP83810548A patent/EP0114027B1/en not_active Expired
- 1983-11-22 DE DE8383810548T patent/DE3375137D1/de not_active Expired
- 1983-11-22 DE DE1994175017 patent/DE19475017I2/de active Active
- 1983-11-22 CA CA000441684A patent/CA1210405A/en not_active Expired
- 1983-11-22 AT AT83810548T patent/ATE31718T1/de active
- 1983-11-22 LU LU88670C patent/LU88670I2/fr unknown
1984
- 1984-06-28 FI FI842615A patent/FI77228C/fi not_active IP Right Cessation
- 1984-07-20 DK DK359284A patent/DK359284D0/da not_active Application Discontinuation
1990
- 1990-04-19 DK DK097890A patent/DK165244C/da not_active IP Right Cessation
- 1990-05-11 JP JP2120164A patent/JPH0347167A/ja active Granted
1991
- 1991-02-06 HK HK111/91A patent/HK11191A/en not_active IP Right Cessation
- 1991-12-20 CY CY1579A patent/CY1579A/xx unknown
1995
- 1995-09-28 NL NL950022C patent/NL950022I2/nl unknown

Also Published As

Publication number	Publication date
NL950022I2 (nl)	1996-12-02
GR79042B (da)	1984-10-02
FI77228C (fi)	1989-02-10
IE832713L (en)	1984-05-22
FI842615A7 (fi)	1984-06-28
IL70286A0 (en)	1984-02-29
EP0114027B1 (en)	1988-01-07
DK165244C (da)	1993-03-22
CA1210405A (en)	1986-08-26
DE3375137D1 (en)	1988-02-11
NL950022I1 (da)	1996-01-02
DK97890D0 (da)	1990-04-19
HUT35642A (en)	1985-07-29
DE19475017I2 (de)	2003-02-20
AU570021B2 (en)	1988-03-03
AU2261283A (en)	1984-06-18
CY1579A (en)	1991-12-20
IL70286A (en)	1987-08-31
HK11191A (en)	1991-02-13
EP0114027A1 (en)	1984-07-25
DK359284A (da)	1984-07-20
JPH0440343B2 (da)	1992-07-02
LU88670I2 (fr)	1996-04-29
DK359284D0 (da)	1984-07-20
ATE31718T1 (de)	1988-01-15
FI77228B (fi)	1988-10-31
JPH0347167A (ja)	1991-02-28
IE56262B1 (en)	1991-06-05
HU204253B (en)	1991-12-30
NZ206338A (en)	1987-08-31
WO1984002131A1 (fr)	1984-06-07
FI842615A0 (fi)	1984-06-28
DK165244B (da)	1992-10-26

Legal Events

Date	Code	Title	Description
1996-02-26	CTFF	Application for supplementary protection certificate (spc) filed	Free format text: CA 1996 00001, 960118
1997-04-21	CTFG	Supplementary protection certificate (spc) issued	Free format text: CA 1996 00001, 960118, EXPIRES: 20080823
2003-12-08	PUP	Patent expired

Publication	Publication Date	Title
DK97890D0 (da)	1990-04-19	Fremgangsmaade til fremstilling af mevalolactonanaloge
AU557691B2 (en)	1987-01-08	2-penem antibiotics and their oxa-aza-, and carba analogues
SE8002292L (sv)	1980-09-27	4-amino-3-kinolinkarboxylsyror och estrar som antisekretoriska anti-ulcerosa foreningar
JPS53135931A (en)	1978-11-28	Lysine ester triisocyanate
FI943508A0 (fi)	1994-07-26	Pyridiinikarboksimidamidiyhdisteet ja niiden käyttö
SE7903976L (sv)	1979-11-10	Nya purinderivat anvendbara sasom icke-adrenenergiska bronkodilatorer
NO840037L (no)	1984-01-05	Cykloalifatiske farmasoeytiske forbindelser
NO834265L (no)	1984-05-23	Fremgangsmaate ved fremstilling av nye 6alfa-methylkortikoider
GB1382744A (en)	1975-02-05	Preparation of polyfluoroalcohols and esters
JPS5549352A (en)	1980-04-09	Cyclic iminocarboxylic acid derivative and its salt
EA199800468A1 (ru)	1998-12-24	25-гидрокси-16-ен-26,27-бисгомохолекальциферолы
JPS5455565A (en)	1979-05-02	Novel thiazolidine derivative
ES540448A0 (es)	1985-12-01	Procedimiento de obtencion de nuevos carbonatos &-clorados
IE791521L (en)	1980-02-10	Thiophenecarboxamido alkyl mercaptans
JPS5210218A (en)	1977-01-26	Preparation of beta-sulfenylacrylamides
JPS52147964A (en)	1977-12-08	Cathode-ray tube
JPS5438647A (en)	1979-03-23	Face lattice concurrently used as eaves
JPS55151555A (en)	1980-11-26	Proline derivatives and their production
JPS5331649A (en)	1978-03-25	Cholesteric compounds
IE812732L (en)	1982-05-21	3-amino steroid compounds
JPS5414961A (en)	1979-02-03	Novel 3-hydroxyazetidine-3-carboxylic derivative
DK325885D0 (da)	1985-07-17	Fremgangsmaade til fremstilling af halogenerede aroyleddikesyreestre
JPS54138537A (en)	1979-10-27	Novel 3-(3,4-dihydroxy-phenyl) serine derivative
JPS53111034A (en)	1978-09-28	Deoxypheganomycin group antibiotics and their preparation
JPS5461170A (en)	1979-05-17	Preparation of coerulein and its analogs